Detail akcie Ultragenyx Pharm online

Business Summary: Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Ultragenyx Pharmaceutical Inc revenues increased 28% to $139.3M. Net loss decreased 11% to $151.1M. Revenues reflect Crysvita segment increase of 52% to $55.1M, Evkeeza segment increase from $3.3M to $11M, Latin America segment increase of 56% to $54.9M, Europe segment increase of 46% to $23.3M. Lower net loss reflects Research and Development decrease of 8% to $145M (expense).